Skip to content

Biopsychosocial Predictors of Nicotine Relapse

Identifying Biomarkers of Stress-induced Neurophysiological Changes and Emotion Regulation Deficits to Predict Relapse During Nicotine Abstinence

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06470321
Acronym
BioNic
Enrollment
200
Registered
2024-06-24
Start date
2022-01-01
Completion date
2025-05-01
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Addiction, Smoking, Smoking Cessation, Tobacco Smoking Behavior

Keywords

Nicotine, Relapse, Vulnerability, Biomarkers, EEG, HRV, Stress Reactivity

Brief summary

This study aims to investigate the associations between emotion regulation ability, stress-induced neural activity changes, and susceptibility to relapse in smokers attempting to quit. Participants will undergo assessments of emotion regulation, neural activity via quantitative electroencephalography (qEEG), and stress responses before and during a 24-hour nicotine abstinence period. They will then participate in a computerized smoking cessation intervention, and their abstinence status will be monitored for 6 months.

Detailed description

The study will examine the unique and interactive effects of emotion regulation ability (a trait-like vulnerability factor) and biomarkers of stress responses (emotion regulation and neural activation changes) prior to smoking cessation, on cravings, abstinence adherence, and response to a smoking cessation intervention. The study will be divided into three main phases: * Ad libitum nicotine use (Day 1): Participants will smoke as usual. Baseline assessments of emotion regulation (heart rate variability), neural activity (qEEG), stress responses (salivary cortisol), and nicotine craving will be conducted before and after exposure to a stress task. * Acute 24-hour abstinence (Day 2): Participants will abstain from smoking for 24 hours. Emotion regulation, neural activity, withdrawal symptoms, and cue-induced cravings will be assessed. * Smoking cessation intervention (Days 3 to 180): Participants will engage in a computerized smoking cessation program. Abstinence will be biochemically verified at 3 and 6 months post-quit. Smoking lapses and time to relapse will also be monitored. The primary outcomes are maintenance of abstinence, smoking lapses, and time to relapse. Secondary outcomes include changes in emotion regulation, neural activity, stress responses, withdrawal symptoms, and cue-induced cravings. The study hypothesizes that smokers who fail to maintain long-term abstinence will exhibit enhanced stress-induced high-frequency qEEG oscillations, disrupted connectivity in emotion regulation brain regions, and emotion regulation deficits. It is also hypothesized that the interplay between these measures will predict smoking cessation outcomes.

Interventions

BEHAVIORALFlexiquit Computerized Smoking Cessation Program

Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.

Sponsors

University of Cyprus
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Intervention Model: Single Group Assignment This is a single-arm study where all participants will receive the same smoking cessation intervention after completing the initial assessments.

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-60 years * Smoking at least 10 cigarettes daily for at least 2 years * Intention to quit smoking * Medication-free

Exclusion criteria

* Presence of psychiatric or medical treatment * Pregnancy * Current unstable medical illness * Recent (prior 6 months) drug or alcohol use disorder * Major Depression * Diagnosis of psychotic disorder

Design outcomes

Primary

MeasureTime frameDescription
Maintenance of AbstinenceMeasured at 3 and 6 month follow-upsDefined as biochemically verified (via expired carbon monoxide) continuous abstinence from smoking for the full 6 month period after the quit date
Time to First Smoking Lapse6 monthsDefined as the number of days between the quit date and the first smoking lapse (smoking even a puff of a cigarette). Smoking lapses will be monitored continuously via self-report.

Secondary

MeasureTime frameDescription
Withdrawal SymptomsBaseline, 24 hoursAssessed via standardized withdrawal symptom questionnaires at baseline and after 24 hours of abstinence.
Emotion RegulationBaseline, 24 hoursMeasured via heart rate variability before and after stress exposure at baseline and 24-hour timepoints
Neural ActivityBaseline, 24 hoursQuantitative EEG spectral power and coherence between brain regions involved in emotion regulation assessed at baseline and after 24-hour abstinence.
Stress ResponsesBaseline, 24 hoursSalivary cortisol levels measured before and after stress exposure at baseline and 24-hour timepoints

Countries

Cyprus

Contacts

Primary ContactPanos Zanos, Ph.D.
zanos.panos@ucy.ac.cy+35722892243

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026